ArticlePloS one2018

Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies.

Rachel C Doran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.